Clinical Trial Update: Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension [Phase 1, Phase 2]

View source ↗

Summary

A pilot Phase 1/2 trial evaluating the safety and efficacy of anakinra for pulmonary hypertension was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Pulmonary Hypertension | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-06-08